ArticleInternal and emergency medicine2026
Diagnostic performance and timeliness of ultrasound-guided core needle biopsy for peripheral lymphadenopathy in Internal Medicine: a multicenter real-world study.
Article in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUltrasound-guided core needle biopsy (CNB) is increasingly used for evaluating peripheral lymphadenopathy, but evidence regarding its implementation in Internal Medicine remains limited. We assessed its diagnostic performance, safety, and diagnostic timeliness in routine clinical practice.
methodsThis retrospective multicenter study included consecutive patients undergoing ultrasound-guided CNB of peripheral lymphadenopathy in five Internal Medicine departments between February 2021 and March 2026. The primary outcome was diagnostic performance. Secondary outcomes included safety, diagnostic timeliness, performance in lymphoma patients, and factors associated with obtaining a definitive diagnosis.
resultsA total of 413 patients were included (median age 62 years; 41.3% women). Lymphoma and carcinoma accounted for 44.1% and 23.7% of final diagnoses, respectively. The first CNB provided a definitive diagnosis in 85.7% of patients and a suggestive diagnosis in 8.0%, yielding an overall diagnostic yield of 93.7%. No major complications occurred. Median time from biopsy request to procedure was 1 day (IQR 0-2), and median time to definitive diagnosis was 10 days (IQR 6-16). Surgical biopsy was required in 9.4% of patients and was associated with longer diagnostic delays (42 vs 9 days; p < 0.001). Among 182 patients with lymphoma, overall diagnostic yield was 93.4%. Lower operator experience and hospital size < 500 beds were independently associated with a lower likelihood of obtaining a definitive diagnosis.
conclusionsUltrasound-guided CNB of peripheral lymphadenopathy performed by internists demonstrated high diagnostic yield, excellent safety, and short diagnostic timelines in a large multicenter real-world cohort. Operator experience and institutional context may influence diagnostic performance.
Indexed as
Identifiers
42853520What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.